The Efficacy of Moxifloxacin-Containing Triple Therapy after Standard Triple, Sequential, or Concomitant Therapy Failure for Helicobacter pylori Eradication in Korea

Kwang Hyun Chung; Dong Ho Lee; Eunhyo Jin; Yuri Cho; Ji Yeon Seo; Nayoung Kim; Sook Hyang Jeong; Jin Wook Kim; Jin-Hyeok Hwang; Cheol Min Shin
November 2014
Gut & Liver;Nov2014, Vol. 8 Issue 6, p605
Academic Journal
Background/Aims: Retreatment after initial treatment failure for Helicobacter pylori is very challenging. The purpose of this study was to evaluate the efficacies of moxifloxacincontaining triple and bismuth-containing quadruple therapy. Methods: A total of 151 patients, who failed initial H. pylori treatment, were included in this retrospective cohort study. The initial regimens were standard triple, sequential, or concomitant therapy, and the efficacies of the two following second-line treatments were evaluated: 7-day moxifloxacincontaining triple therapy (rabeprazole 20 mg twice a day, amoxicillin 1,000 mg twice a day, and moxifloxacin 400 mg once daily) and 7-day bismuth-containing quadruple therapy (rabeprazole 20 mg twice a day, tetracycline 500 mg 4 times a day, metronidazole 500 mg 3 times a day, and tripotassium dicitrate bismuthate 300 mg 4 times a day). Results: The overall eradication rates after moxifloxacin-containing triple therapy and bismuth-containing quadruple therapy were 69/110 (62.7%) and 32/41 (78%), respectively. Comparison of the two regimens was performed in the patients who failed standard triple therapy, and the results revealed eradication rates of 14/28 (50%) and 32/41 (78%), respectively (p=0.015). The frequency of noncompliance was not different between the two groups, and there were fewer adverse effects in the moxifloxacin-containing triple therapy group (2.8% vs 7.3%, p=0.204 and 25.7% vs 43.9%, p=0.031, respectively). Conclusions: Moxifloxacin-containing triple therapy, a recommended second-line treatment for initial concomitant or sequential therapy failure, had insufficient efficacy.


Related Articles

  • The Pediatrician's Dilemma. Nelson, Leonard B. // Journal of Pediatric Ophthalmology & Strabismus;Jan/Feb2006, Vol. 43 Issue 1, p13 

    The article focuses on the use of moxifloxacin to prevent the spread of bacterial conjunctivitis. It was learned that gram-negative pathogens have been the major cause of bacterial conjunctivitis. Recently, gram-positive pathogens have assumed a more prominent role in causing bacterial...

  • Susceptibility of Stenotrophomonas maltophilia to Moxifloxacin, Trovafloxacin, Ofloxacin and Ciprofloxacin. Hawley, H.B.; Polenakovik, H.M.; Czachor, J.S.; Mueller, S.S. // Drugs;Dec1999 Supplement 2, Vol. 58 Issue 6, p214 

    Examines the in vitro susceptibility of clinical isolates of Gram-negative bacterium Stenotrophomonas maltophilia to newer quinolones. Materials and methods; Results.

  • Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days Moxifloxacin based therapy for the eradication: a randomized controlled trial. Bago, Josip; Majstorovic, Karolina; Belošic-Halle, Željka; Kucišec, Nastja; Bakula, Vinko; Tomic, Monika; Bago, Petra; Troskot, Rosana // Annals of Clinical Microbiology & Antimicrobials;2010, Vol. 9, p13 

    Introduction: Antibiotic resistance decreases success of Helicobacter pylori (Hp) eradication. Recently published results show low rate of resistance and better compliance with moxifloxacin based regiments. Aims&methods: Whether 7 days moxifloxacin with lansoprasole and amoxycillin can be...

  • Impact of Fluoroquinolone Administration on the Emergence of Fluoroquinolone-Resistant Gram-Negative Bacilli from Grastrointestinal Flora. Richard, Pascale; Delangle, Marie Helene; Raffi, Francois; Espaze, Eric; Richet, Herve // Clinical Infectious Diseases;1/1/2001, Vol. 32 Issue 1, p162 

    Discusses a study which assessed the risk factors for acquisition of fluoroquinolone-resistant, gram-negative organisms in the gastrointestinal tract of hospitalized patients. Use of fluoroquinolone for the treatment of infections; Methods used; Analysis of risk factors for colonization with...

  • Prevalence of Ciprofloxacin Resistance Among Gram-Negative Bacilli at a Specialist Hospital in Saudi Arabia. Ahmad, Shamweel // Bangladesh Journal of Medical Science;Oct2012, Vol. 11 Issue 4, p317 

    Background: Resistance to antimicrobials of different structural classes including fluoroquinolones has arisen in a multitude of bacterial species both in the community and the hospitals. This may complicate the therapeutic management of infections. Decreased susceptibility to fluoroquinolones...

  • Comparative Activity of 7 Quinolones Against Non-Glucose Fermenting Gram-Negative Bacilli Isolated from Cancer Patients. Balakrishnan, M.; Mago, H.; LeBlanc, B.; Rolston, K.V.I. // Drugs;Dec1999 Supplement 2, Vol. 58 Issue 6, p190 

    Evaluates the in vitro activity of seven quinolones against non-glucose fermenting Gram-negative bacilli isolated from clinical specimens of cancer patients. Materials and methods; Results.

  • Clinafloxacin Antibacterial Activity. Ednie, L.M.; Jacobs, M.R.; Appelbaum, P.C. // Drugs;Dec1999 Supplement 2, Vol. 58 Issue 6, p217 

    Characterizes the in vitro activity of clinafloxacin compared with other quinolones. Results of MIC testing of several ciprofloxacin-susceptible and -resistant strains; Gram-negative nonfermenters that were generally resistant to quinolones.

  • Comparative In Vitro Activity of Grepafloxacin Against Selected Mutants and Clinical Isolates. Soussy, C.J.; Leblanc, F. // Drugs;Dec1999 Supplement 2, Vol. 58 Issue 6, p138 

    Evaluates the in vitro activity of grepafloxacin by agar dilution against quinolone-resistant mutants of Gram-negative bacilli and Enterococcus faecalis and their parent strains. Results; Discussion.

  • Effect of Quinolones on Intestinal Ecology. Edlund, C.; Nord, C.E. // Drugs;Dec1999 Supplement 2, Vol. 58 Issue 6, p65 

    Quinolones have a selective effect on the normal human intestinal microflora. Published data on 13 different quinolone agents [ciprofloxacin, enoxacin, norfloxacin, ofloxacin, pefloxacin, lomefloxacin, levofloxacin, sparfloxacin, rufloxacin, sitafloxacin (DU-6859a), gatifloxacin, trovafloxacin...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics